LivaNova PLC (NASDAQ:LIVN) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC cut its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 14.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 170,365 shares of the company's stock after selling 29,200 shares during the period. Cubist Systematic Strategies LLC owned 0.31% of LivaNova worth $7,890,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its position in LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after acquiring an additional 265,291 shares during the period. Capital Research Global Investors grew its holdings in shares of LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after purchasing an additional 258,730 shares during the period. Dimensional Fund Advisors LP increased its position in LivaNova by 8.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock worth $60,710,000 after purchasing an additional 107,693 shares in the last quarter. Emerald Advisers LLC raised its holdings in LivaNova by 8.2% in the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock valued at $34,850,000 after buying an additional 57,035 shares during the period. Finally, AQR Capital Management LLC lifted its position in LivaNova by 79.3% during the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock valued at $34,214,000 after buying an additional 328,313 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Down 0.0 %

Shares of LIVN traded down $0.01 during trading on Friday, reaching $44.06. The company's stock had a trading volume of 1,063,416 shares, compared to its average volume of 637,153. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $63.57. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 104.90 and a beta of 0.84. The company has a fifty day moving average of $37.89 and a two-hundred day moving average of $45.15.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several recent research reports. The Goldman Sachs Group dropped their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Mizuho reduced their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Robert W. Baird raised their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday. Finally, StockNews.com cut LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LivaNova currently has an average rating of "Moderate Buy" and a consensus price target of $59.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.